It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Decode metabolic disease with human-relevant models and system-wide insights that enable smarter decisions, faster, in a controlled and collaborative research environment.
Understanding the mechanisms behind metabolic disease is essential to developing effective therapies.
Sygnature Discovery supports this journey with integrated capabilities from target identification and molecule design to in vitro and in vivo modelling giving you the tools to explore disease progression and treatment response with precision.
Metabolic diseases disrupt normal pathways that regulate energy, glucose, and lipid balance. Our scientists have been advancing metabolic drug discovery for over two decades from the registration of Sibutramine to preclinical work on Empagliflozin. With deep expertise and a collaborative mindset, we help you move from insight to outcome faster.
Our in vivo metabolic models simulate disease progression and treatment response in controlled environments. We offer a broad portfolio, from generically modified animals to models induced by diet or chemicals, tailored to your research needs.
Key Benefits
Our state-of-the-art facilities and advanced technologies allow us to identify and optimize compounds with strong efficacy and safety profiles. We work closely with you to deliver customized solutions that align with your program goals.
Human-relevant models
Replicate key features of human metabolic disease, offering predictive insights into treatment outcomes.
Controlled environments
Rigorously standardized study conditions ensure consistency and reproducibility, giving you confidence in every data point and decision.
System-wide insights
Explore how organs interact and respond to treatment with whole-body investigations that reveal mechanisms of action and therapeutic impact.
in vivo models – therapeutic indications
Our in vivo models offer high predictive validity, giving you confidence in candidate selection and optimization.
With over 20 years of experience in dietary-induced models and genetically obese animals, we’re well-equipped to support obesity projects.
DIO Mouse and Rat Model
Zucker Rat Model
OB/OB Mouse Model
Models and strategies relevant to diseases such as diabetes, Cushing’s disease, congenital hyperinsulinaemia and more.
Glucocorticoid-Induced Insulin Resistance Rat Model
DIO Mouse and Rat Model
ob/ob Mouse Model
Zucker (Fatty) Rat Model
Years of experience in working with models of Type 2 diabetes including supporting partners whose therapeutics received regulatory approval.
STZ/HFD Mouse and Rat Model
db/db Mouse Model
ZDF Rat Model
ZSF-1 Rat Model
Our kidney models enable detailed investigation of renal function, injury, and repair. With expertise spanning acute and chronic kidney disease, we provide translational in vivo platforms that support efficacy testing, biomarker discovery, and mechanistic insight.
STZ/HFD Mouse and Rat Model
ZSF-1 Rat Model
Adriamycin Mouse Model
Anti-GBM Mouse and Rat Model
LPS Rat and Mouse Model
ex vivo Kidney Slices
Liver models provide a powerful means to study metabolic, inflammatory, and toxicological pathways. Extensive histology expertise is integrated with clinical readouts and functional assessments to deliver comprehensive insights into liver disease and therapeutic impact.
Chlorine Deficient (CD) Mouse Model
H-FCC Mouse Model
H-FCC ob/ob Mouse Model
Cardio-renal models capture the complex interplay between heart and kidney function in health and disease. Studies may integrate blood pressure monitoring, renal biomarkers, and extensive molecular characterization to deliver mechanistic insight and translational endpoints that support therapeutic development.
ZSF-1 Rat Model
Metabolic Profiling
We combine in vivo models with validated analytical endpoints to assess efficacy and mode of action. Our profiling services capture real-time physiological and behavioral changes, helping you understand how treatments affect whole-body metabolism.
In-life profiling includes:
Body weight, food and water intake
Can be assessed in lean and obese animals.
Body Temperature
Non-invasive measurement of core temperature to monitor physiological status or assess treatment response.
Energy Expenditure
RER, food/water intake and locomotor activity.
Glucose and insulin tolerance
Serial sampling and analysis following glucose/insulin challenge in lean and obese animals.
Feeding studies
Acute and chronic (palatable diet, reverse phase feeding)
Behavioural specificity
Video tracking to assess precise changes in activity and behavior.
Body composition
Characterized by DEXA or chemical methods
Muscle function in vivo
Grip strength (longitudinal assessment).
Energy content
Determined by bomb calorimetry (e.g., faeces, urine, diet).
Gastric emptying
Paracetamol absorption, phenol red methods in rats and mice.
Blood pressure
Tail-cuff (non-invasive) systolic/diastolic measurement in conscious animals.
Glomerular filtration rate
Urine output and solute excretion to assess renal clearance.
ex vivo analysis
Our ex vivo platforms complement in-life finding with molecular and biochemical endpoints. These validated assays provide detailed insights into organ-specific responses and help link systematic effects to underlying mechanisms.
Biochemical assays
Liver Panel Screen
Assess liver function and detect liver injury or disease such as ALT, AST, ALP, albumin, protein, Triglyceride, cholesterol panel, NEFA.
Gene expression analysis
Pancreatic insulin content
Changes in total pancreatic insulin can be a cost-effective assessment and often a good surrogate marker where changes in β-cell mass may be expected.
Protein analysis
Kidney function
Assess renal health, filtration, and electrolyte balance: blood urea nitrogen (BUN / urea), plasma creatinine, estimated GFR (eGFR), urine albumin, protein and creatine.
Histology and immunohistochemistry
Metabolic Disease Solutions
Sygnature Discovery’s metabolic offering supports drug discovery from early screening to candidate selection. We use validated animal models and profiling platforms to identify novel targets and assess therapeutic potential. Whether you’re exploring obesity, diabetes, or fatty liver disease, our team delivers the insights and data you need to move forward with confidence.
Explore cutting-edge insights into small molecule innovations driving obesity and weight…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Yes, in order to underpin the quality of our studies, Sygnature has grown up and managed our own cohorts of DIO mice for over 20 years.
Yes. Sygnature ’s DIO model is validated with the comparator’s semaglutide and tirzepatide. Further the model has been used to assess customer compounds in combination with, and upon withdrawal of, these standards of care.
No, Sygnature’s aim is to help our customers with the progression of their drug discovery. We have no internal drug discovery projects such that we would be competing with our partners.
Yes, Sygnature offers integrated drug discovery and has in-house bioanalysis capabilities.
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
